194 related articles for article (PubMed ID: 36970148)
1. Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives.
Nowak RP; Che J; Ferrao S; Kong NR; Liu H; Zerfas BL; Jones LH
RSC Med Chem; 2023 Mar; 14(3):501-506. PubMed ID: 36970148
[TBL] [Abstract][Full Text] [Related]
2. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
[TBL] [Abstract][Full Text] [Related]
3. Molecular glues targeting GSPT1 in cancers: A potent therapy.
Zhang D; Lin P; Lin J
Bioorg Chem; 2024 Feb; 143():107000. PubMed ID: 38029571
[TBL] [Abstract][Full Text] [Related]
4. On Ternary Complex Stability in Protein Degradation: In Silico Molecular Glue Binding Affinity Calculations.
Weiss DR; Bortolato A; Sun Y; Cai X; Lai C; Guo S; Shi L; Shanmugasundaram V
J Chem Inf Model; 2023 Apr; 63(8):2382-2392. PubMed ID: 37037192
[TBL] [Abstract][Full Text] [Related]
5. Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component.
Nayek U; Basheer Ahamed SI; Mansoor Hussain UH; Unnikrishnan MK; Abdul Salam AA
Comput Biol Chem; 2022 Dec; 101():107776. PubMed ID: 36252444
[TBL] [Abstract][Full Text] [Related]
6. Trends in Neosubstrate Degradation by Cereblon-Based Molecular Glues and the Development of Novel Multiparameter Optimization Scores.
Szewczyk SM; Verma I; Edwards JT; Weiss DR; Chekler ELP
J Med Chem; 2024 Jan; 67(2):1327-1335. PubMed ID: 38170610
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy.
Costacurta M; He J; Thompson PE; Shortt J
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834536
[TBL] [Abstract][Full Text] [Related]
8. Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide.
Furihata H; Yamanaka S; Honda T; Miyauchi Y; Asano A; Shibata N; Tanokura M; Sawasaki T; Miyakawa T
Nat Commun; 2020 Sep; 11(1):4578. PubMed ID: 32929090
[TBL] [Abstract][Full Text] [Related]
9. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Surka C; Jin L; Mbong N; Lu CC; Jang IS; Rychak E; Mendy D; Clayton T; Tindall E; Hsu C; Fontanillo C; Tran E; Contreras A; Ng SWK; Matyskiela M; Wang K; Chamberlain P; Cathers B; Carmichael J; Hansen J; Wang JCY; Minden MD; Fan J; Pierce DW; Pourdehnad M; Rolfe M; Lopez-Girona A; Dick JE; Lu G
Blood; 2021 Feb; 137(5):661-677. PubMed ID: 33197925
[TBL] [Abstract][Full Text] [Related]
10. From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation.
Oleinikovas V; Gainza P; Ryckmans T; Fasching B; Thomä NH
Annu Rev Pharmacol Toxicol; 2024 Jan; 64():291-312. PubMed ID: 37585660
[TBL] [Abstract][Full Text] [Related]
11. p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.
Nguyen TV; Li J; Lu CJ; Mamrosh JL; Lu G; Cathers BE; Deshaies RJ
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):3565-3571. PubMed ID: 28320958
[TBL] [Abstract][Full Text] [Related]
12. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
[TBL] [Abstract][Full Text] [Related]
13. USP15 antagonizes CRL4
Nguyen TV
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators.
Liu L; Sun R; Liu H; Ren C; Zhou Y; Qiu X; Kong Y; Jiang B; Yang X
Eur J Med Chem; 2023 Feb; 247():115016. PubMed ID: 36577219
[TBL] [Abstract][Full Text] [Related]
15. Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library.
Powell CE; Du G; Che J; He Z; Donovan KA; Yue H; Wang ES; Nowak RP; Zhang T; Fischer ES; Gray NS
ACS Chem Biol; 2020 Oct; 15(10):2722-2730. PubMed ID: 32865967
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potential novel CRBN modulators by virtual screening and bioassay.
Xiong F; Kong L; Chen L; Xue M; Cao F; Zhang S; Li H; Yan H; Li Y; Zuo Z
Eur J Med Chem; 2022 Jun; 236():114355. PubMed ID: 35413617
[TBL] [Abstract][Full Text] [Related]
17. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
18. Development of sulfonyl fluoride chemical probes to advance the discovery of cereblon modulators.
Liu Y; Nowak RP; Che J; Donovan KA; Huerta F; Liu H; Metivier RJ; Fischer ES; Jones LH
RSC Med Chem; 2024 Feb; 15(2):607-611. PubMed ID: 38389883
[TBL] [Abstract][Full Text] [Related]
19. Photoswitchable Molecular Glues Enable Optical Control of Transcription Factor Degradation.
Arp CJ; Reynders M; Sreekanth V; Kokkonda P; Pagano M; Choudhary A; Trauner D
bioRxiv; 2023 Apr; ():. PubMed ID: 37066279
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship analysis of novel GSPT1 degraders based on benzotriazinone scaffold and its antitumor effect on xenograft mouse model.
Takwale AD; Kim EY; Jang Y; Lee DH; Kim S; Choi Y; Kim JH; Lee DY; Kim Y; Lee SM; Lee HK; Nam HJ; Lee JY; Cho JH; Moon JH; Lee GS; Kim JH; Kim P; Park CH; Hwang JY
Bioorg Chem; 2022 Oct; 127():105923. PubMed ID: 35717803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
